ACE2 mimetic antibody potently neutralizes all SARS-CoV-2 variants and fully protects in XBB.1.5 challenged monkeys
Fenwick, C.; Turelli, P.; Duhoo, Y.; Lau, K.; Herate, C.; Marlin, R.; Lamrayah, M.; Campos, J.; Leuenberger, L.; Farina, A.; raclot, c.; Genet, V.; Fiscalini, F.; Cesborn, J.; Perez, L.; Bosquet, N.; Contreras, V.; Lheureux, K.; relouzat, f.; Abdelnabi, R.; Foo, C. S.-Y.; Neyts, J.; leyssen, p.; Levy, Y.; Pojer, F.; Stahlberg, H.; Le Grand, R.; Trono, D.; Pantaleo, G.
Show abstract
The rapid evolution of SARS-CoV-2 to variants with improved transmission efficiency and reduced sensitivity to vaccine-induced humoral immunity has abolished the protective effect of licensed therapeutic human monoclonal antibodies (mAbs). To fill this unmet medical need and protect vulnerable patient populations, we isolated the P4J15 mAb from a previously infected, vaccinated donor, with <20 ng/ml neutralizing activity against all Omicron variants including the latest XBB.2.3 and EG.1 sub-lineages. Structural studies of P4J15 in complex with Omicron XBB.1 Spike show that the P4J15 epitope shares [~]93% of its buried surface area with the ACE2 contact region, consistent with an ACE2 mimetic antibody. Although SARS-CoV-2 mutants escaping neutralization by P4J15 were selected in vitro, these displayed lower infectivity, poor binding to ACE2, and the corresponding escape mutations are accordingly rare in public sequence databases. Using a SARS-CoV-2 XBB.1.5 monkey challenge model, we show that P4J15 confers complete prophylactic protection. We conclude that the P4J15 mAb has potential as a broad-spectrum anti-SARS-CoV-2 drug.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants 98%
- Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model 97%
- Broadly neutralizing antibodies target the coronavirus fusion peptide 97%
Similar papers in this journal
- Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153 97%
- A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection 97%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 96%
Similar papers in this journal
Similar papers in this journal
- Antibody inhibition of influenza A virus assembly and release 96%
- The effect of single mutations in Zika virus envelope on escape from broadly neutralizing antibodies 96%
- Deep mutationally scanned (DMS) CHIKV E3/E2 virus library maps viral amino acid preferences and predicts viral escape mutants of neutralizing CHIKV antibodies 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.